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The complete sequence of a 94 amino acid human seminal plasma polypeptide exhibiting inhibin-like activi- 
ty is presented. This molecule, called /I-inhibin, selectively and specifically suppresses the release of pituitary 
FSH in vivo as well as in vitro. It does not affect the secretion of LH. Such a novel acidic protein contains 
a very basic C-terminal segment which is easily cleaved by mild tryptic digestion. It is predicted that the 
FSH inhibiting activity may reside within this region of the molecule. This would imply a post Gln-Arg 
cleavage to release the basic C-terminal active moiety. 
t%Inhibin Pituitary FSH release Amino acid sequence Human seminal plasma 
1. INTRODUCTION 
Many peptides can be found in extracts of 
seminal plasma and gonads. Among them is a rat 
90 amino acid basic polypeptide, SVS-IV [ 11, 
whose secretion is stimulated by testosterone [2]. 
The complete amino acid sequence of another 
seminal plasma 109 amino acid protein, PDC-109, 
has been recently reported [3]. There is now ample 
evidence that the secretion of follicle stimulating 
hormone (FSH) by the anterior lobe of the 
pituitary gland is regulated by a non-steroidal hor- 
mone of gonadal origin, termed ‘inhibin’ [4-61. 
Inhibin-like activity has been found to be 
associated with peptides of various sizes, depend- 
ing on the purification methods used and sources 
of extraction from gonads and their secretions 
from different species [7-l 11. Human seminal 
plasma is also found to contain polypeptides of 
varying molecular masses, exhibiting inhibin-like 
activity [12-141. Recently, the structure [15] and 
activity [16] of a 31 amino acid human inhibin-like 
peptide and its synthetic replica have been de- 
scribed. The purification and partial N-terminal 
30-residue sequence of yet another high molecular 
mass human seminal plasma polypeptide with 
inhibin-like activity has been reported [17]. 
We present he complete amino acid sequence of 
this latter human protein, termed ,&inhibin, and 
report on its biological activity both in vitro and in 
vivo. 
2. MATERIALS AND METHODS 
2.1. Purification of human ,&inhibin 
The isolation and purification of the polypeptide 
sequences in this study have been reported earlier 
[17]. The final purification was achieved by 
reverse-phase high performance liquid chroma- 
tography (HPLC) using ap-Bondapak Cl8 column 
(Waters) eluted with an acetonitrile/heptafluoro- 
butyric acid (HFBA) gradient as reported else- 
where [18]. 
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2.2. Amino acid analysis and se~ue~c~~g 
procedure 
Amino acid analyses of the reduced and carbox- 
ymethylated peptides were done in duplicate 
following hydrolysis in 5.7 M HCl in vacua at 
110°C for 24, 48 and 72 h. 
Automatic amino-teeing Edman degradation 
of the reduced and carboxymethylated peptides 
was performed using 0.33 M Quadrol program on 
a Beckman 89OC sequenator equipped with a Se- 
quemat P6 autoconverter and a model SC-5 10 con- 
troller. Prior to sequencing, 3 precycles were run 
with 3 mg Polybrene (Aldrich) as a carrier. 
Modifications of the running order of cycles in- 
cluded a double coupling on cycle 1, and double 
cleavages at all suspected praline residues. Further- 
more, to eliminate minor contaminating sequences 
and dimi~sh ba~kgro~d a~~um~ation~ o- 
phth~aldehyde blocking at certain proline residues 
was done [19]. Phenylthiohydautoin (PTH) amino 
acids were identified and quantitated by HPLC on 
a Varian LCSSOO/Vista 402 system as in [20,21]. 
2.3. Tlyptic, ~~y~~try~ti~ and CNBr dig~tio~ 
The reduced and carboxymethylated &inhibin 
was digested at 37°C for 3 h with HPLC-purified 
trypsin [22], using an enzyme/substrate weight 
ratio of 1: 20 in 0.1 M Na2HP04, pH 8.5. The pep- 
tides were purified by HPLC as in 1181. Similarly, 
ch~o~sin digestion was ~rformed with 
HPLC-purified enzyme. CNBr digestion was 
found to be more efficient on the native rather 
than the carboxymethylded ,&inhibin. This was 
performed at room temperature, in the dark, in 
70% formic acid for 18 h. The mole ratio of CNBr 
to methio~ne used was 500: 1. Following 
lyophihzation, the mixture was reduced and car- 
boxymethylated, then desalted and purified by 
HPLC. 
2.4. Bioassays 
The biological activity of ~-inhibin was 
measured by its specific suppression of FSH 
release, both in vitro [23], and in vivo [12]. 
2.4.1. In vitro mouse pituitary assay 1231 
WhoIe pituitaries of 2O-day old mice were prein- 
cubated for 30 min in Dulbecco’s Modified Eagle’s 
medium (DME) at pH 7.5, oxygenated with 95% 
02-5% CO2 at 37°C. After the preincubation 
350 
period, the medium was replaced by 500 pl of fresh 
DME in the absence (control) or presence of 
various doses of @-inhibin (calculated by quan- 
titative amino acid composition). After 1 h of in- 
cubation, 500,ul of DME (control) or 500~1 of 
DME containing 3 ng of LH-RH was added to 
each tube. Incubation proceeded for another 3 h, 
after which the concentration of FSH and LH in 
the medium were quantitated by a radioreceptor 
assay [23]. 
2.4.2. In vivo castrated adult male rat assay 1121 
Holtzman male rats @O-day-old) were bilaterally, 
castrated, two weeks prior to assay. The animals 
were injected intramuscularly once daily for 3 days 
with either 0.1 ml saline (control) or 0.1 ml con- 
taining various doses of fl-inhibin. 4 h after the last 
injection, the animals were bled and their sera col- 
lected. The plasma levels of FSH and LH were 
determined by RIA using NIAMDD-rat-FSH- 
RP-1 and NIAMDD-rat-LH-RP-1, respectively. 
3. RESULTS 
3.1. Complete sequence determination 
The amino acid analysis of the purified ,&inhibin 
is shown in table 1, together with that of two tryp- 
tic fragments obtained. It can be seen that the 
molecule seems to be composed of about 87-89 
amino acids, excluding tr~toph~. Noteworthy is 
the absence of alanine in this molecule. 
The results of the N-terminal sequence of the 
first 81 amino acids are presented in fig.lA. The 
initial yield of this sequence was around 17 nmol, 
and the overall repetitive yield, obtained from the 
linear regression line, was calculated to be 95.07%. 
Although this peptide was purified at least 3 times 
on HPLC, it was found that 2 contaminating se- 
quences were present. One of them was later iden- 
tified as the segment 83-94 of the complete 
molecule (8% cont~ination). The other minor 
cont~inant (3%) was of unknown sequence. 
Neither contaminant contained proline at position 
6, and hence both were eliminated following the o- 
phthalaldehyde block. This sequence was repeated 
twice and it was found that unless a double coupl- 
ing/cleavage was done in cycles 35 and 36, a major 
problem would occur causing a drastic increase in 
the carryover from cycle to cycle. This strategy was 
also used for cycles 62, 63, where the same pro- 
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Table 1 
Amino ,&Inhibin Tryptic segments 
acid 
24 h 48 h 72 h Sequence 67-94b Sequence 86-94” Sequence 
LYS 10.8(11) lOS(11) 10.8(11) 11 7.0(7) 7 1.00) 1 
His 1.1(l) 1.1(l) 1.1(l) 1 - - 
Arg 2.1(2) 2.0(2) 2.1(2) 2 - 
Asp llS(12) 11.5(12) 11.8(12) 12 1.9(2) 2 - - 
Thr 7.5(8) 7.1(7) 7.0(7) 8 1.0(l) 1 1.0(l) 1 
Ser 5.7(6) 4.7(5) 5.0(5) 7 1.7(2) 2 2.1(2) 2 
GlU lO.l(lO) 9.8(10) 10.4(10) 10 2.9(3) 3 1.4(l) 1 
Pro 5.2(5) 4.9(5) 5.1(5) 5 1.0(l) 1 - - 
GUY 4.3(4) 4.1(4) 4.7(5) 5 0.7(l) 1 1.1(l) 1 
Ala - - - - - 
cysa 9.2(9) 8.8(9) 9.4(9 - 10) 10 1.2(l) 2 0.6( 1) 1 
Val 6.4(6) 6.4(6) 6.1(6) 6 2.7(3) 3 0.7(l) 1 
Met 0.8(l) 0.6( 1) 0.8(l) 1 - - - 
Ile 6.2(6) 6.1(6) 6.2(6) 6 3.1(3) 3 1.1(l) 1 
Leu 2.3(2) 2.1(2) 2.2(2) 2 - - 
Tyr 4.0(4) 3.8(4) 3.5(4) 4 0.8(l) 1 - 
Phe 2.1(2) 2.0(2) 2.1(2) 2 1.0(l) 1 - - 
Trp N.D. N.D. N.D. 2 N.D. 1 N.D. 1 
Total 89 87 89 94 28 10 
a Determined as S-carboxymethylcysteine 
b 48 h hydrolysis 
’ 24 h hydrolysis 
N.D., not determined. Numbers in parentheses represent nearest integer. Sequence, the predicted values from the 
sequence of ,&inhibin 
blern recurred. Interestingly, both regions repre- 
sent Asp-Asn-Cys bonds. 
An identical sequence was also obtained follow- 
ing CNBr fragmentation, where the sequence start- 
ing at Asp 20 up to Ser 90, was determined. This 
allowed the extension of the sequence of the 
molecule to residue 90 (not shown). Similarly, one 
of the chymotryptic fragments purified was se- 
quenced and umambiguously confirmed residues 
53-66 of the molecule. 
In order to obtain the complete sequence of this 
polypeptide, its reduced and carboxymethylated 
form was subjected to trypsin digestion. It was 
found that the earliest cleaved peptide represented 
the carboxyterminal sequence, showing that the 
peptide bond ArgG-11%7 was very sensitive to this 
enzyme. The complete sequence of this tryptic 
fragment is shown in fig.lB. This sequence was 
also confirmed at least 3 times. The initial and 
repetitive yields for this sequence were found to be 
2.4 run01 and %.39!i’o. As can be seen from fig.lB, 
the PTH yields cannot be fitted to a single regres- 
sion line. Rather, two other lines can be deduced 
following residues 13 and 25, both being Glu 
residues helping the anchorage of the residual 
polypeptide to the Polybrene carrier. Nevertheless 
this sequence confirms residues 67-81 and 67-90 
obtained with the whole molecule and one of its 
CNBr fragments, and the whole chain to the 
carboxyterminus of fl-inhibin. 
Carboxypeptidase Y digestion of Binhibin 
shows the release of only one amino acid, namely 
Ile, even after 8 h reaction. This is taken as 
evidence that IleN represents the C-terminal 
residue of Binhibin. Glycine is known to be resis- 
tant sometimes to the action of this exopeptidase, 
explaining the resistance to further cleavage 
following Ile~. Furthermore, the amino acid com- 
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Fig. 1. Phenylthiohydantoin (PTH) yield obtained 
during the sequence of the carboxymethylated fl-inhibin 
(A) and its C-terminal tryptic fragment (B). The 
sequence of the whole &inhibin allowed the 
unambiguous elucidation of the first 81 residues. The 28 
residue C-terminal tryptic segment was sequenced to its 
carboxy-terminal Be residue. 
position of the C-terminal segment sequenced 
(table 1) shows a good fit with the deduced se- 
quence, and the composition of another tryptic 
peptide (table 1) matches well the determined se- 
quence of residues 86-94. Finally, the amino acid 
composition of the whole &inhibin molecule fits 
well the proposed sequence shown in fig.2. 
3.2. Bioactivity of native @-inhibin 
Fig.3 shows the bioactivities of &inhibin, both 
in vitro (fig.fA) and in vivo (fig.3B). In both cases, 
Complete Sequence of Human beta-Inhibin 
1 5 10 I.3 
NH&‘. Ser Cya Tyr Phe Ile Pro Asn Clu Cly Vd Pro Gly Asp Ser Thr 
20 25 30 
Ar# Lys cyn Met Asp teu Lys Cly AsI2 Lys HIS Pro Ile As” ser 
35 40 45 
Glu Trp Clr, Thr Asp Asn Cys CIu Thr Cys Thr Cys Tyr Clu Thr 
50 55 80 
Clu Ile Ser Cys Cys Thr Leu VaJ Ser Thr Pro Vel Cly Tyr Asp 
Clu Trp GIy Ile .COOH 
Fig.2. Proposed complete amino acid sequence of 
human fl-inhibin. Identical residues found at 
homologous positions upon alignment (starting at 
position 59) of the 31 amino acid sequence of the 
inhibin-like peptide [15,16] and of the human ,&inhibin 
are enclosed in boxes. The proposed disulfide bridge 
linking CYSTS to Cyss7 is also indicated by a solid line. 
z-_--+-_-A___-•____* 
L 
3 IO 30 100 300 
PEPTlOE , np,m,, 
_____r____.$____T_ k * l * 
300 Kxu moo 
Fig.3. Bioactivity of human &inhibin in vitro using the 
mouse pituitary assay (A) and in vivo using the castrated 
rat assay (B). It is seen that in both assays FSH release 
is inhibited in a dose-dependent manner by ,&inhibin. 
The * means that the inhibition is statistically 
significant. In (A), each point represents FSH and LH 
duplicate measurements in the medium of at least 5 
different mouse pituitaries for each dose, using a 
radioreceptor assay. In (B), each point represents 
duplicate measurements of plasma levels of FSH and LH 
in at least 6 different castrated rats per dose, using a 
specific RIA. In all cases, the concentration of fl-inhibin 
was calculated based on its quantitative amino acid 
analysis and its calculated M of 10704. 
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this polypeptide selectively inhibits the release of 
FSH, but not LH. The potency in the in vitro assay 
is about lo-15-times higher than the in vivo one. 
For example, 143.4 ng (13.4 pmol) of ,&inhibin 
cause a 45.6% suppression of FSH levels in the in 
vitro assay, whereas it takes 2.87 pg (268 pmol) to 
observe a 58.5% depression in the in vivo assay. 
Moreover, the peptide is active both in the mouse 
(in vitro) and the rat (in vivo). Lastly, it can be seen 
that the FSH inhibition observed in vitro, in the 
mouse pituitary assay, is biphasic. Namely, from 
32-160 ng (3-15 pmol) of @-inhibin, a dose- 
dependent suppression of FSH is observed, 
whereas at a higher dose of 578 ng (54 pmol) the 
peptide is less effective (fig.3A). 
4. DISCUSSION 
From these data, it is proposed that &inhibin is 
composed of 94 amino acids. This polypeptide, 
which is not glycosylated, migrates on sodium 
dodecyl sulphate-polyacrylamide gel electro- 
phoresis (SDS-PAGE) with an apparent mole- 
cular mass of 14 kDa. The calculated molecular 
mass, based on its primary structure, is 10704 Da. 
This difference in molecular mass is probably due 
to the abnormal migration of this peptide on 
SDS-PAGE. Similar observations have been made 
previously for many other basic polypeptides, in- 
cluding rat SVS-IV protein [1], a non-glycosylated 
polypeptide of 90 amino acids which migrates on 
SDS-PAGE with an apparent molecular mass of 
17kDa [l]. 
The sequence of the first 30 residues of ,&inhibin 
presented here agrees entirely with the one 
reported for that segment of the molecule by 
authors in [17]. However, the amino acid composi- 
tion of the whole ,&inhibin differs significantly. 
Since both papers are based on the same batch of 
@-inhibin, the interpretation of the difference can 
be attributed to contamination of the original 
batch by an Ala-containing peptide. Indeed, upon 
repurification of this batch by HPLC in 
HFBA/acetonitrile, we were able to eliminate most 
of this contamination, which represented up to 
30% of the total. The so-purified fl-inhibin is vir- 
tually devoid of alanine. 
Examination of the sequence reveals a number 
of repetitive segments. First, the triad Asp-Asn- 
Cys appears twice, at residues 35-37 and 62-64. 
Next, the pairs Lys-Lys and Thr-Cys appear 3 
times at residues 69-70,80-81, 84-85 and 39-40, 
41-42, 86-87, respectively. Other pairs also ap- 
pear twice, including Lys-Asp, Ser-Cys, Ser-Glu, 
Ser-Thr, Glu-Trp, Glu-Thr, Cys-Tyr and Val-Ser. 
The meaning of such repetitive sequences is not 
clear at present. 
A computer data bank search on the possible 
homology of the &inhibin sequence to any known 
protein or segment hereof, using a mutation data 
matrix developed at the National Biomedical 
Research Foundation in Georgetown University, 
revealed no significant homologies (<25%). A 
comparison between the sequence of fl-inhibin and 
the one reported for another basic human inhibin- 
like peptide [ 15,161 reveals that only 5 residues, as 
shown in fig.2, match out of 31. These include Lys 
61, 69, 85 and Val-Val 77-78. Interestingly, a 
homology can be found between the sequences of 
human-&inhibin and bovine seminal plasma 
PDC-109 [3]. Two stretches of 4 amino acids can 
be found in both molecules, namely Glu-Thr-Cys- 
Thr 38-41, and Tyr-Asp-Lys-Asp 59-62. In both 
cases, however, it can be concluded that the se- 
quence presented for @-i&bin is a novel one. 
Concerning the 4 pairs of basic residues found in 
this sequence, namely Arg-Lys 16-17 and Lys-Lys 
69-70, 80-81 and 84-85, these could represent 
potential cleavage sites for a maturation enzyme 
[24]. Furthermore, it can be noted that 11%~ is 
preceded by a Lys-X-X-X-Gln-Arg- segment. An 
identical segment is also found in the sequence of 
residues 59-64 of the bovine seminal plasma pro- 
tein PDC-109 [3]. In the case of human pro- 
somatostatin, the cDNA sequence [25] predicts 
that in order to cleave it to somatostatin 28 
[26-281, a cleavage following Gin-Arg in the 
stretch Arg-X-X-X-Gln-Arg- [25] is necessary. It is 
therefore quite conceivable that in the case of ,& 
inhibin, one of its maturation products would be 
the 28 residue C-terminal peptide starting and end- 
ing in 11%~ and Ilepc respectively. This would 
generate, similar to somatostatin, a 2bresidue pep- 
tide with one potential disulfide bridge. Indeed, 
preliminary data on the inhibin-like activity of a 
synthetic peptide comprising residues 67-94 with a 
closed disulfide bridge demonstrate the plausibility 
of this hypothesis. Our results [18] indicate that the 
inhibin-like activities of both ,&inhibin l-94 and 
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&inhibin 67-94 are equipotent on a mole to mole 
basis. Based on these data, it is proposed that 
Gys73 is linked via a disulfide bond to CysS7 in the 
native &inhibin. We have not yet defined the in- 
terlocking potential disulfide bridge pattern bet- 
ween the other 8 Cys residues predicted in the N- 
terminal sequence of fl-inhibin (see fig.2). It is, 
therefore, tempting to speculate on the possibility 
that the segment following the Lys-X-X-X-Gln- 
Arg- sequence in PDC-109, namely residues 
65- 109 [lo], might exhibit some inhibin-like activi- 
ty. This possibility is further supported by a match 
of 7 residues between the sequences of P-inhibin 
67-94 and the segment 65-109 of PDC-109. 
However, this hypothesis will have to be ex- 
perimentally verified. 
Finally, from the results presented, it can be 
concluded that &inhibin is a very potent novel 
peptide which effectively and selectively inhibits 
the release of FSH, both in vitro and in vivo. In 
vitro, it is quite active at concentrations below 
107 ng/ml (10 pmol/ml). Furthermore, the rela- 
tion between the observed and reported specific in- 
hibition of FSH release, both in vitro and in vivo, 
by the &inhibin and by the inhibin-like peptide 
previously described [ 15,161 is intriguing. 
Although highly dissimilar in structure, it can be 
seen that both peptides are able to exhibit potent 
biological activities in the assays used. The 
biphasic nature of this inhibition, as observed with 
,&inhibin, is not yet adequately explained, but suf- 
fice to say that a similar phenomenon has been 
observed previously [29]. Much more work is 
necessary before the physiological potential of 
human ,&inhibin can be fully assessed. 
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